Detalle Publicación

ARTÍCULO
Venous thrombosis within 30 days after vaccination against SARS-CoV-2 in a multinational venous thromboembolism registry
Autores: Bikdeli, B. (Autor de correspondencia); Jiménez, D.; Demelo-Rodríguez, P.; Galeano-Valle, F.; Porras, J. A.; Barba, R.; Ay, C.; Malý, R.; Braester, A.; Imbalzano, E.; Rosa, V.; Lecumberri Villamediana, Ramón; Siniscalchi, C.; Fidalgo, A.; Ortiz, S.; Monreal, M.; RIETE Investigators
Título de la revista: VIRUSES-BASEL
ISSN: 1999-4915
Volumen: 14
Número: 2
Páginas: 178
Fecha de publicación: 2022
Resumen:
Background: Venous thromboembolism (VTE)-including deep vein thrombosis, pulmonary embolism, and cerebral venous sinus thrombosis (CVST)-may occur early after vaccination against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We sought to describe the site, clinical characteristics, and outcomes of VTE after vaccination against SARS-CoV-2. Methods: In a prospective study using the Registro Informatizado de Enfermedad TromboEmbolica (RIETE) platform, patients with VTE 4-30 days after vaccination against SARS-CoV-2 (1 February 2021 through 30 April 2021) were included. VTE patients recruited from the same centers into RIETE in the same months in 2018-2019 were selected as the reference group. All-cause mortality and major bleeding were the main study outcomes. Results: As of 30 April 2020, 102 patients with post-vaccination VTEs had been identified (28 after adenovirus-based vaccination [ChAdOx1 nCov-19; AstraZeneca] and 74 after mRNA-based vaccination [mRNA-1273; Moderna, and BNT162b2; Pfizer]). Compared with 911 historical controls, patients with VTE after adenovirus-based vaccination more frequently had CVST (10.7% vs. 0.4%, p < 0.001) or thrombosis at multiple sites (17.9% vs. 1.3%, p < 0.001), more frequently had thrombocytopenia (40.7% vs. 14.7%, p < 0.001), and had higher 14-day mortality (14.3% vs. 0.7%; odds ratio [OR]: 25.1; 95% confidence interval [CI]: 6.7-94.9) and major bleeding rates (10.3% vs. 1.0%, OR: 12.03, 95% CI: 3.07-47.13). ...